1-苯并噻酚-2-基甲胺 | 6314-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-苯并噻酚-2-基甲胺
• 中文别名: 苯并噻吩-2-甲胺
• 英文名称: N-[(benzo[b]thiophen-2-yl)methyl]amine
• 英文别名: benzo[b]thiophen-2-ylmethanamine；1-benzothiophen-2-ylmethanamine
• CAS: 6314-43-8
• 化学式: C₉H₉NS
• mdl: MFCD00965305
• 分子量: 163.243
• InChiKey: WKYFWFHTABURGB-UHFFFAOYSA-N

物化性质

• 熔点：
  58 °C
• 沸点：
  110-12°C 0,25mm

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险品运输编号：
  UN 3259
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  应存于2-8℃环境中，避免光照，并在惰性气体保护下保存。

SDS

Name:	1-Benzothiophen-2-ylmethylamine 97% Material Safety Data Sheet
Synonym:
CAS:	6314-43-8

Section 1 - Chemical Product MSDS Name:1-Benzothiophen-2-ylmethylamine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6314-43-8	1-Benzothiophen-2-ylmethylamine		unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6314-43-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 110 - 112 deg C @0.25mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NS
Molecular Weight: 163

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6314-43-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Benzothiophen-2-ylmethylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6314-43-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6314-43-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6314-43-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯并噻酚-2-基甲胺 生成 4,5,6,7-Tetrahydro-1H-benzimidazole-5-carboxylic acid ((benzo[b]thiophen-2-yl)methyl)amide
  参考文献：
  名称：

  Imidazole compounds

  摘要：

  一种新型的咪唑杂环化合物类，包括它们的药物组合物以及在治疗和/或预防与组织胺H3受体相关的疾病和疾病的用途。更具体地说，这些化合物对于治疗和/或预防与组织胺H3受体相互作用有益的疾病和疾病是有用的。

  公开号：

  US20020058659A1
• 作为产物：
  描述：

  苯并噻吩-2-羧酸 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成 1-苯并噻酚-2-基甲胺
  参考文献：
  名称：

  设计和合成基于杂芳基的苯磺酰胺衍生物作为H5N1甲型流感病毒的有效抑制剂†

  摘要：

  甲型流感病毒是一种包膜的负性单链RNA病毒，可引起发热的呼吸道感染，对人类健康乃至全世界的生命都构成了具有临床挑战性的威胁。更令人震惊的是高致病性禽流感（HPAI）菌株（如H5N1）的出现，其在人类感染中的死亡率（60％）比季节性流感菌株高得多。在这项研究中，新的杂芳基苯磺酰胺衍生物系列被确定为M2质子通道抑制剂。对结构-活性关系的系统研究和分子对接研究表明，磺酰胺部分和2,5-二甲基取代的噻吩作为核心结构在抗流感活性中起着重要作用。在衍生物中，化合物11k具有对H5N1病毒的优异抗病毒活性，EC 50值为0.47μM，选择性指数为119.9，与参考药物金刚烷胺相当。

  DOI：

  10.1039/c8md00474a
• 作为试剂：
  描述：

  2-氨甲基-5-甲基噻吩 、 4-methyl-2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)thiazole-5-carboxylic acid 以 1-苯并噻酚-2-基甲胺 为溶剂， 以43%的产率得到2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-4-methyl-N-((5-methylthiophen-2-yl)methyl)thiazole-5-carboxamide
  参考文献：
  名称：

  ORGANIC COMPOUNDS

  摘要：

  本发明提供了调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A去饱和酶活性的方法以及包含这些衍生物的药物组合物。

  公开号：

  US20090156615A1

文献信息

• Design, Synthesis, and Biological Evaluation of Novel Tri- and Tetrasubstituted Imidazoles as Highly Potent and Specific ATP-Mimetic Inhibitors of p38 MAP Kinase: Focus on Optimized Interactions with the Enzyme’s Surface-Exposed Front Region
  作者：Stefan A. Laufer、Dominik R. J. Hauser、David M. Domeyer、Katrin Kinkel、Andy J. Liedtke

  DOI：10.1021/jm701529q

  日期：2008.7.1

  region (hydrophobic region II) of the enzyme led to the identification of extremely potent p38 MAPK inhibitors with p38 IC 50 values in the low nanomolar range. Approximately 90 pyridinylimidazole-based compounds with a range of potencies against p38alpha MAP kinase were further investigated for their ability to inhibit the release of tumor necrosis factor-alpha (TNFalpha) and/or interleukin-1beta (IL-1beta)

  描述了新型2,4,5-和1,2,4,5-取代的2-硫代咪唑的合成，生物学测试和SAR。评估吡啶基部分2位上的氨基，氧基或硫氧基取代基对抑制剂效能和对p38丝裂原活化蛋白激酶（p38 MAPK）的选择性的贡献以及使细胞色素P450（CYP450）抑制作用最小化的能力。与酶表面暴露的前区（疏水区II）正向相互作用的极性取代的（环）脂族氨基取代基（例如四氢吡喃基氨基）的引入导致鉴定出p38 IC50值为50的强效p38 MAPK抑制剂。低纳摩尔范围。进一步研究了大约90种具有对p38alpha MAP激酶具有一定效力的吡啶基咪唑基化合物，它们具有抑制人类全血释放肿瘤坏死因子α（TNFalpha）和/或白介素1beta（IL-1beta）的能力。一些最有前途的候选药物除p38alpha以外，还针对一组17种不同的激酶进行了选择性分析，和/或测试了它们对许多代谢相关CYP450同工酶的相互作用潜能。
• Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
  申请人：Tachdjian Catherine

  公开号：US20050084506A1

  公开（公告）日：2005-04-21

  The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

  本发明涉及发现，某些非天然存在的非肽酰胺化合物和酰胺衍生物，如草酰胺、脲和丙烯酰胺，可用作风味或口味调节剂，例如风味或调味剂和风味或口味增强剂，更具体地说，是用于食品、饮料和其他可食用或口服药品或组合物的风味或口味调节剂，包括鲜味（味精的“鲜味”）或甜味调节剂，鲜味或甜味调味剂以及鲜味或甜味增强剂。
• Substituted bis-amide metalloprotease inhibitors
  申请人：Sucholeiki Irving

  公开号：US20070155739A1

  公开（公告）日：2007-07-05

  This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。
• Base-Promoted C→N Acyl Rearrangement: An Unconventional Approach to α-Amino Acid Derivatives
  作者：Iratxe Ugarriza、Uxue Uria、Luisa Carrillo、Jose L. Vicario、Efraim Reyes

  DOI：10.1002/chem.201402514

  日期：2014.9.8

  N‐alkyl aminomalonates undergo a fast and selective intramolecular C→N acyl rearrangement reaction in the presence of a strong base, leading to N‐protected glycinates in excellent yield. Moreover, the fact that the reaction proceeds through a nucleophilic enolate intermediate has been used for implementing a tandem rearrangement/alkylation sequence that has been applied to the preparation of synthetically

  我们发现，在强碱的存在下，N-烷基氨基丙二酸酯会进行快速且选择性的分子内C→N酰基重排反应，从而以极高的收率得到N-保护的甘氨酸盐。此外，反应通过亲核的烯醇式中间体进行的事实已被用于实施串联重排/烷基化序列，该序列已被用于以非常简单和简单的方式制备合成上相关的非蛋白的叔N-烷基和叔N-烷基α-氨基酸。可靠的方法。
• Virtual Screening Approach to Identifying a Novel and Tractable Series of <i>Pseudomonas aeruginosa</i> Elastase Inhibitors
  作者：Simon Leiris、David T. Davies、Nicolas Sprynski、Jérôme Castandet、Lilha Beyria、Michael S. Bodnarchuk、Jonathan M. Sutton、Toby M. G. Mullins、Mark W. Jones、Andrew K. Forrest、T. David Pallin、Paduri Karunakar、Sathish Kumar Martha、Battu Parusharamulu、Ramesh Ramula、Venkatesh Kotha、Narender Pottabathini、Srinivasu Pothukanuri、Marc Lemonnier、Martin Everett

  DOI：10.1021/acsmedchemlett.0c00554

  日期：2021.2.11

  Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis

  需要新的疗法来治疗囊性纤维化 (CF) 患者的慢性细菌感染。导致这些感染的最常见病原体是铜绿假单胞菌，尽管进行了强化抗生素治疗，但它仍然存在于 CF 患者的肺部。铜绿假单胞菌弹性蛋白酶（也称为 LasB 或假溶素）是导致CF 患者中铜绿假单胞菌感染的发病机制和持续存在的关键毒力决定因素。LasB 在假单胞菌毒力中的关键作用使其成为开发 CF 治疗辅助药物的良好靶点。在这里，我们讨论了通过虚拟筛选和计算机辅助药物设计 (CADD) 发现一系列新的 LasB 抑制剂及其优化化合物29和39 ( K i = 0.16 μM 和 0.12 μM，分别)。